Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1.53	1.56	1.36	0.29	-
Revenue Growth (YoY)	-1.54%	14.31%	378.25%	-	-
Cost of Revenue	43.77	48.03	38.8	29.69	12.52
Gross Profit	-42.23	-46.47	-37.43	-29.41	-12.52
Selling, General & Admin	18.5	19.06	17.56	14.21	9.69
Operating Expenses	18.5	19.06	17.56	14.21	9.69
Operating Income	-60.73	-65.53	-54.99	-43.62	-22.21
Interest & Investment Income	2.95	4.5	1.04	0.1	0.08
EBT Excluding Unusual Items	-57.78	-61.03	-53.95	-43.51	-22.13
Merger & Restructuring Charges	-10.9	-	-	-	-
Asset Writedown	-24.72	-1.59	-1.32	-	-
Pretax Income	-93.4	-62.62	-55.27	-43.51	-22.13
Income Tax Expense	0.04	0.06	0.01	-	-
Net Income	-93.44	-62.68	-55.28	-43.51	-22.13
Preferred Dividends & Other Adjustments	-	-	-	-	0.12
Net Income to Common	-93.44	-62.68	-55.28	-43.51	-22.24
Shares Outstanding (Basic)	65	50	30	13	9
Shares Outstanding (Diluted)	65	50	30	13	9
Shares Change (YoY)	30.74%	64.72%	132.83%	51.17%	4150.62%
EPS (Basic)	-1.43	-1.26	-1.83	-3.35	-2.59
EPS (Diluted)	-1.43	-1.26	-1.83	-3.35	-2.59
Free Cash Flow	-72.35	-64.35	-43.55	-29.21	-22.92
Free Cash Flow Per Share	-1.11	-1.29	-1.44	-2.25	-2.67
Operating Margin	-3959.13%	-4205.90%	-4034.48%	-15303.51%	-
Profit Margin	-6090.94%	-4023.11%	-4055.61%	-15267.72%	-
Free Cash Flow Margin	-4716.36%	-4130.36%	-3195.08%	-10247.37%	-
EBITDA	-60.26	-65.25	-53.92	-42.61	-22.11
D&A For EBITDA	0.47	0.28	1.07	1	0.1
EBIT	-60.73	-65.53	-54.99	-43.62	-22.21

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q